How We Approach Weight-Loss Peptides
Weight-loss peptides do a narrower, more specific job than a GLP-1: instead of suppressing appetite, they protect lean mass, target visceral fat, and improve how your cells burn fuel. Here is how a provider decides which one fits, and where peptides genuinely help versus where they are oversold.
In this article
Key Takeaways
- Weight-loss peptides are a different tool than a GLP-1. A GLP-1 suppresses appetite; the peptides we use do a narrower job: protect lean mass, target visceral fat, and improve metabolic efficiency.
- Peptides are not a one-to-one substitute for a GLP-1. They are body-composition and metabolic tools, strongest when layered on top of nutrition and resistance training, not a replacement for them.
- AOD-9604 is the most direct fat-metabolism option; Tesamorelin is the choice for stubborn visceral fat; MOTS-c targets metabolic efficiency and insulin sensitivity rather than fat loss itself.
- Tesamorelin has the strongest human data, AOD-9604 the most mixed, and MOTS-c is largely preclinical. None is an FDA-approved weight-loss drug. We say so plainly.
- The clearest win for peptides is alongside or after a GLP-1, where preserving lean mass and limiting fat regain matters most.
The Short Answer
Our approach in one paragraph
Weight-loss peptides are a different tool than a GLP-1. A GLP-1 drug like semaglutide works mainly by suppressing appetite. The metabolic peptides we work with do a more specific job: AOD-9604 pushes fat breakdown, Tesamorelin targets the deep visceral fat that resists diet and exercise, and MOTS-c improves how your cells handle fuel. None of them is an appetite-suppressing weight-loss drug, and they are not a substitute for one. The honest framing is that these peptides change body composition and protect lean mass, and they are at their best layered on top of good nutrition and training, alongside a GLP-1, or used to hold the line when someone is coming off one. This guide is about how a provider decides which peptide fits, and where the science actually supports the claim.
A Different Tool Than a GLP-1
It is worth being clear about how peptides relate to GLP-1s, because most weight-loss conversations in 2026 start there. A GLP-1 drug such as semaglutide or tirzepatide is a powerful, FDA-approved appetite-suppressing medication. It works largely by changing how hungry you feel. The weight-loss peptides covered here are a different category that works through different mechanisms, and they are not trying to compete on appetite suppression.
What peptides offer is a more focused set of jobs, and a more honest pitch. They are aimed at the things appetite suppression handles poorly or not at all: preserving the lean muscle that calorie restriction tends to strip, selectively reducing visceral fat, and improving the metabolic machinery underneath. For a large number of patients, especially those who have already used a GLP-1, that is exactly the part of the problem still left unsolved. The two approaches are complementary far more than they are rivals.
Three Jobs Peptides Actually Do
The reason we use more than one weight-loss peptide is that they are not interchangeable. Each one attacks a different mechanism, and most of the value comes from matching the mechanism to the problem in front of you rather than reaching for a default. Three jobs cover most of what people actually need.
| Peptide | Mechanism | Best for | |
|---|---|---|---|
| AOD-9604 | AOD-9604 | A modified fragment of growth hormone that stimulates fat-cell breakdown and inhibits new fat formation, without the blood-sugar or growth effects of full HGH | General fat loss and a direct push on fat metabolism |
| Tesamorelin | Tesamorelin | A GHRH analog that raises natural growth-hormone output, selectively mobilizing deep abdominal fat while sparing subcutaneous fat and lean muscle | Stubborn visceral fat that resists diet and exercise |
| MOTS-c | MOTS-c | A mitochondrial-derived peptide that activates AMPK, improves insulin sensitivity, and enhances fat oxidation | Metabolic efficiency, fuel handling, and energy rather than fat loss itself |
Notice that only two of these are really about losing fat, and the third is about how efficiently your cells run. That distinction matters. MOTS-c is not a fat-loss drug. It is a metabolic-efficiency peptide that often gets added when insulin sensitivity, energy, and fuel handling are part of someone’s picture, not when the only goal is a smaller number on the scale.
Matching the Peptide to the Goal
The mechanism logic gets concrete when you map it onto real situations. None of this is a prescription, and your provider makes the actual call at intake, but it shows how the decision tends to break down.
| Situation | Typical starting point | Why | |
|---|---|---|---|
| General fat loss, want a metabolic push | General fat loss, want a metabolic push | AOD-9604 | Direct effect on fat breakdown without GH-style side effects |
| Stubborn deep belly fat | Stubborn deep belly fat | Tesamorelin | Strongest data on visceral fat specifically, spares lean mass |
| Energy, insulin sensitivity, fuel handling | Energy, insulin sensitivity, fuel handling | MOTS-c | Targets metabolic efficiency rather than fat loss itself |
| Losing muscle on or after a GLP-1 | Losing muscle on or after a GLP-1 | GH-axis support (Tesamorelin or CJC-1295/Ipamorelin) | Preserving lean mass is the priority, not more appetite suppression |
For the full physician-reviewed ranking with dosing context, see the best peptides for weight loss. Many patients end up combining two of these, because direct fat metabolism and lean-mass preservation are different problems, and a provider may decide both are worth addressing at once.
Alongside and After a GLP-1
The clearest case for weight-loss peptides is not as a GLP-1 alternative at all. It is around the GLP-1. Two situations come up constantly. The first is muscle loss during GLP-1 therapy: the appetite drop that makes the drug work also makes it hard to eat enough protein, and a meaningful share of the weight people lose on a GLP-1 is lean tissue rather than fat. The second is the rebound after stopping.
The rebound problem
Most people regain a large share of their GLP-1 weight within a year of stopping the medication, and a disproportionate amount of what comes back is fat rather than the muscle that was lost. That is the opposite of the body composition most people wanted. A peptide protocol after a GLP-1 is built around holding the line: preserving lean mass, limiting visceral fat regain, and supporting metabolic rate. We cover the full playbook in the coming-off-Ozempic transition guide, and the lean-mass question specifically in muscle loss on GLP-1s.
An Honest Word on the Evidence
A responsible version of this article has to be straight about the research, because the weight-loss space is full of overstatement. The three peptides do not share an evidence base, and lumping them together as proven would be wrong. Tesamorelin has the strongest human data of the group. FDA-recognized trials showed roughly a 15 to 18 percent reduction in visceral fat, but that work was done in a specific HIV-associated lipodystrophy population, and applying it to general weight loss is a reasonable extrapolation rather than a settled fact.
AOD-9604 has human trials, but the results on overall weight have been more mixed than its reputation suggests. Its clearest rationale is mechanistic: it pushes lipolysis and limits new fat formation. MOTS-c is largely preclinical, meaning the encouraging data on AMPK activation and insulin sensitivity comes mostly from animal and laboratory studies, not large human trials. None of these is an FDA-approved weight-loss drug, and all are prescribed as compounded medications. That is not a reason to dismiss them, and it is not a reason to treat them as miraculous either. It is a reason to use them under physician supervision, with realistic expectations set up front.
Who This Fits
Ideal for
People focused on body composition rather than just scale weight, who want to preserve lean mass while losing fat. Anyone targeting stubborn visceral fat that has resisted diet and exercise. People coming off a GLP-1 who want to hold their results, or on a GLP-1 and worried about losing muscle. Patients who already have solid nutrition and resistance training in place and want an additive metabolic layer, and who want a physician-reviewed prescription rather than a research-chemical purchase.
Consider alternatives if
If you are looking for the large appetite-driven weight loss a GLP-1 produces, peptides are not a substitute for that effect. If your nutrition and training are not yet in place, peptides will underdeliver. Avoid these peptides in pregnancy and breastfeeding, and discuss carefully with a provider if you have an active or recent cancer, since the growth-hormone axis is involved with several of them. Your prescriber makes these calls at intake.
PeRx ships AOD-9604, Tesamorelin, and MOTS-c as ready-to-use, refrigerated vials given as a small subcutaneous injection, with no mixing on your end. Your dose and schedule are set by your prescribing provider based on your intake and goals. For what to expect and when, the results timeline walks through pacing.
Frequently Asked Questions
Related Guides
Continue reading about peptides and protocols that pair well with this guide.
AOD-9604: 2026 Fat-Loss HGH Fragment Guide
Growth hormone burns fat. It also raises blood sugar, swells joints, and can trigger abnormal growth. In 1993, an Australian biochemist isolated the 16 amino acids responsible for fat metabolism and nothing else. That fragment became AOD-9604. It sailed through early clinical trials, stumbled at Phase IIb, earned FDA safety clearance, and is now finding a second life through compounding pharmacies and emerging joint-health research.
Is AOD-9604 FDA Approved? Status & Access (2026)
No, but AOD 9604 has a more extensive clinical trial history than most compounded peptides. It completed Phase 2 clinical trials in Australia for obesity, enrolling over 300 patients. Australia's Therapeutic Goods Administration (TGA) classified it as safe. The development program was discontinued for efficacy reasons at the Phase 2 dose, not safety concerns.
Tesamorelin 2026: FDA-Approved GHRH for Visceral Fat
Most peptides in the compounding space have animal studies and early clinical signals. Tesamorelin has two Phase 3 randomized controlled trials, 816 patients, CT-measured visceral fat data, and an FDA approval. It is a synthetic analog of growth hormone-releasing hormone that triggers your pituitary to produce its own GH in a natural, pulsatile pattern. The result: targeted visceral fat loss without the side effects of injecting growth hormone directly.
Find the weight-loss peptide that fits your goal
Take our 5-minute health assessment. A licensed provider reviews your body composition, history, and goals, then prescribes the peptide that actually fits, whether that is direct fat metabolism, visceral fat, or lean-mass support. Shipped ready to use. No labs required to start.
Medical Disclaimer
The information provided on this website, including all articles, guides, and educational content, is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this site should be construed as a substitute for professional medical advice from a qualified healthcare provider.
The majority of peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the indications described. They are classified as bulk drug substances and are available only through a licensed prescribing provider and compounding pharmacy. All treatments require a valid prescription and provider oversight.
The majority of published research on peptide therapies has been conducted in preclinical (animal) models. While early human data is encouraging, comprehensive clinical trial data remains limited for most peptide compounds. Individual results may vary significantly based on health status, injury type, and other factors. No specific outcomes are guaranteed.
Certain peptides discussed on this site are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned by major sports organizations including the NFL, NCAA, UFC, NBA, MLB, NHL, and PGA. If you are subject to anti-doping testing, consult your governing body before considering any peptide therapy.
Statements on this website have not been evaluated by the Food and Drug Administration. Products and therapies discussed are not intended to diagnose, treat, cure, or prevent any disease.
© 2026 Wellness MD Group PC DBA PeRx. All rights reserved.